Effects of Vitamin B3 in Patients With Ataxia Telangiectasia

Status Completed

Clinical Trial Summary

This clinical trial investigates the effects of nicotinamide riboside (vitamin B3) on the disease course of patients with ataxia telangiectasia. Patients will be treated during four consecutive months with nicotinamide riboside (25mg/kg/day), followed by a washout period of two months. Main study parameters/endpoints: Ataxia, dysarthria, quality of life, laboratory parameters.

Clinical Trial Description

Rationale: Ataxia Telangiectasia (A-T) is an autosomal recessively inherited neurodegenerative disorder, with a high cancer risk, that also affects the immune and respiratory system. Therapy for A-T is restricted to symptomatic treatment including rehabilitation care, combined with infection prevention and treatment, and screening for pulmonary dysfunction and malignancies. A-T is caused by mutations in the ATM gene. The ATM protein plays a pivotal role in more than 100 different biochemical processes, among which cellular energy metabolism, cell signaling, and DNA repair. Nicotinamide adenine dinucleotide (NAD+) is an essential molecule in many of these processes and studies have shown that NAD+ deficiency plays a role in disease mechanisms underlying DNA repair disorders such as A-T. NAD+ is available in food, but can also be synthesized in the body from its precursors nicotinamide, nicotinic acid, and nicotinamide riboside (NR), as a group called "vitamin B3". Treatment of experimental A-T animal models with NR showed beneficial effects. The aim of this study is to investigate whether treatment with NR during a period of six months may have positive effects on the disease course of patients with A-T. Objective: To investigate the effects of NR on the disease course of patients with ataxia telangiectasia. Study design: Single center, interventional, explorative, open-label proof of concept study. Study population: Patients with A-T (age >2 years). Intervention (if applicable): Patients will be treated with nicotinamide riboside (25mg/kg/day), during four consecutive months, followed by a washout period of two months. Main study parameters/endpoints: Ataxia, dysarthria, quality of life, laboratory parameters. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03962114
Study type	Interventional
Source	Radboud University Medical Center
Contact
Status	Completed
Phase	Phase 2
Start date	March 18, 2019
Completion date	March 1, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02345135` - Susceptibility to Infections in Ataxia Telangiectasia	N/A
Active, not recruiting	`NCT04991701` - A National Retrospective Population Based Cohort Study of the Natural History of Ataxia Telangiectasia
Active, not recruiting	`NCT05531890` - Comparative Bioavailability of Betamethasone Oral Solution Metered Spray (GTX-102) in Healthy Subjects	Phase 1
Recruiting	`NCT05692596` - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Completed	`NCT05252819` - Whole Body MRI for Cancer Surveillance in A-T
Recruiting	`NCT03357978` - Susceptibility to Infections, Tumor Risk and Liver Disease in Patients With Ataxia Telangiectasia	N/A
Withdrawn	`NCT02309632` - Pancreatic Cancer Screening of High-Risk Individuals in Arkansas	N/A
Not yet recruiting	`NCT06324877` - Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With Nicotinamide Riboside	N/A
Not yet recruiting	`NCT01075438` - Immunogenicity of Pneumococcal Vaccines in Ataxia-telangiectasia Patients	N/A
Completed	`NCT04513002` - Ataxia-telangiectasia: Treating Mitochondrial Dysfunction With a Novel Form of Anaplerosis	Phase 2
Completed	`NCT05471310` - Videoocular Assessment of Eye Movement Activity in an Ataxia Telangiectasia
Active, not recruiting	`NCT04870866` - NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia	Phase 2
Recruiting	`NCT03563053` - Open-label, Long-term, Extension Treatment Using Intra-Erythrocyte Dexamethasone Sodium Phosphate in Patients With Ataxia Telangiectasia Who Participated in the IEDAT-02-2015 Study	Phase 3
Recruiting	`NCT05692622` - Home-based Complex Intervention for Children With Ataxia Telangiectasia	N/A
Recruiting	`NCT04037189` - Treatment of Leukemia and Lymphoma in Children With Ataxia Telangiectasia
Not yet recruiting	`NCT04887311` - MBM-01 (Tempol) for the Treatment of Ataxia Telangiectasia	Phase 2
Active, not recruiting	`NCT00951886` - The Validity of Forced Expiratory Maneuvers in Ataxia Telangiectasia Studied Longitudinally	N/A
Recruiting	`NCT03759678` - N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)	Phase 2
Recruiting	`NCT01052623` - Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)	Phase 4
Enrolling by invitation	`NCT04605523` - Neurofilament Light- Chain in Ataxia Telangiectasia

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.